These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11715354)

  • 1. Pharmacoeconomic impact of HOPE.
    Ostergren JB; Björholt I; Andersson F; Kahan T
    Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
    Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
    An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
    Gerstein HC
    Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.
    Smith MG; Neville AM; Middleton JC
    Intern Med J; 2003; 33(9-10):414-9. PubMed ID: 14511193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
    Grover SA; Coupal L; Lowensteyn I
    Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
    Björholt I; Andersson FL; Kahan T; Ostergren J
    J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
    Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
    J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events.
    Capri S; Perlini S
    Curr Med Res Opin; 2005 Jun; 21(6):913-21. PubMed ID: 16003858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
    Lamy A; Yusuf S; Pogue J; Gafni A;
    Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.
    Aurbach A; Russ W; Battegay E; Bucher HC; Brecht JG; Schädlich PK; Sendi P
    Swiss Med Wkly; 2004 Jul; 134(27-28):399-405. PubMed ID: 15389357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.
    Carroll CA; Coen MM; Piepho RW
    Ann Pharmacother; 2003 Mar; 37(3):327-31. PubMed ID: 12639157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
    Malik IS; Bhatia VK; Kooner JS
    Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical decision making and the expected value of information.
    Willan AR
    Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the relevance of the HOPE study in general practice?
    Kennedy J; Mogensen CE; Ball SG; Castaigne AD; Commerford PJ; Distiller L; Fisher BM; Gonzalez-Jaunatey J; Nosadini R; Novials A; Ostergren J; Palma-Gámiz J; Perrone-Filardi P; Schipperheijn JJ; Senges J; Trevisan R
    Int J Clin Pract; 2001 Sep; 55(7):449-57. PubMed ID: 11594254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.
    Erhardt L; Ball S; Andersson F; Bergentoft P; Martinez C
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):256-66. PubMed ID: 10170450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More than just hype.
    Yusuf S; Dagenais G
    CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.